Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share. The options were awarded at no upfront cost, expire on March 31, 2036, and vest in equal monthly installments over one year beginning March 31, 2026. This filing reflects a compensation-related equity award rather than an open-market purchase or sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schwab Andrew J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 75,000 options Exercise price: $0.615 per share Underlying shares: 75,000 shares +3 more

6 metrics

Option grant size 75,000 options Stock Option (Right to Buy) granted to director

Exercise price $0.615 per share Exercise price for underlying common stock

Underlying shares 75,000 shares Common Stock underlying the option

Expiration date March 31, 2036 Option expiration for the grant

Vesting start March 31, 2026 Vests in equal monthly installments over one year

Post‑grant derivative holdings 75,000 options Total options held after this transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "0.6150""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-03-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The stock option vests in equal monthly installments over the one year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: "Common Stock""

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 06:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwab Andrew J.

(Last)

(First)

(Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO

CALIFORNIA

94111

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.615	03/31/2026		A		75,000		⁽¹⁾	03/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Remarks:

	/s/ Punit S. Dhillon, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Skye Bioscience (SKYE) disclose about Andrew J. Schwab in this Form 4?

Skye Bioscience disclosed that director Andrew J. Schwab received a stock option grant for 75,000 shares of common stock. The award is a compensation-related option, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.

How many Skye Bioscience (SKYE) options did Andrew J. Schwab receive?

Andrew J. Schwab received stock options covering 75,000 shares of Skye Bioscience common stock. These options were granted as a single award and represent his reported derivative holdings following the transaction in this Form 4 filing.

What is the exercise price of Andrew J. Schwab’s Skye Bioscience (SKYE) options?

The stock options granted to Andrew J. Schwab have an exercise price of $0.615 per share. This means he can choose to buy Skye Bioscience common shares at $0.615 if he exercises the options after they vest and before expiration.

When do Andrew J. Schwab’s Skye Bioscience (SKYE) options vest?

The options granted to Andrew J. Schwab vest in equal monthly installments over one year, beginning March 31, 2026. This creates a 12‑month vesting schedule, gradually making portions of the 75,000‑share option exercisable each month.

What is the expiration date of Andrew J. Schwab’s Skye Bioscience (SKYE) options?

Andrew J. Schwab’s stock options expire on March 31, 2036. He must exercise any vested portions of the 75,000‑share grant before that expiration date; otherwise, the right to purchase those shares at $0.615 per share will lapse.

Does this Skye Bioscience (SKYE) Form 4 show any stock being bought or sold on the market?

No, the Form 4 reports a grant of stock options to Andrew J. Schwab rather than a market trade. It reflects a compensation-related award, with no open-market buying or selling of Skye Bioscience common shares disclosed in this transaction.